January 23, 2017

NeoChord Names J. Alex Martin Chairman of the Board

ST. LOUIS PARK, Minn., Jan. 23, 2017 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced the appointment of […]

Read On ›
January 9, 2017

ProNAi Relaunched as Sierra Oncology to Advance DDR-Based Cancer Drugs

VANCOUVER, Jan. 9, 2017 /CNW/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage drug development company advancing targeted therapeutics for the treatment of patients with cancer, today announced it has changed its corporate name to Sierra […]

Read On ›
December 8, 2016

Drug made in Kalamazoo could be first to treat Parkinson’s | Woodtv.com

GRAND RAPIDS, Mich. (WOOD) — A diabetes drug developed in Kalamazoo is showing promise in treating Parkinson’s disease. The Van Andel Research Institute says human trials will begin next year for MSDC-0160, which was created […]

Read On ›
December 7, 2016

Van Andel Institute: Diabetes drug slows experimental Parkinson’s disease progression, human trials to begin next year

GRAND RAPIDS, Mich. (Dec. 7, 2016)—A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s […]

Read On ›
November 9, 2016

First Patient Treated in U.S. Randomized Trial of NeoChord’s, Off-Pump, Minimally Invasive Repair for Degenerative Mitral Regurgitation

ST. LOUIS PARK, Minn., Nov. 09, 2016 (GLOBE NEWSWIRE) —  NeoChord, Inc., a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced the first use […]

Read On ›
November 1, 2016

ConcertoHealth® Closes $30 Million Growth Financing; New Equity Will Fuel Expansion of Primary Care Medical Home Model and Population Health Platform

IRVINE, CA–(Marketwired – Nov 1, 2016) – ConcertoHealth, the nation’s leading provider of healthcare services for complex, frail, elderly, and Medicare-Medicaid dual-eligible patients, today announced the completion of a $30 million round of financing from […]

Read On ›
May 15, 2016

Sales near for Delphinus ultrasonic breast cancer detector

Delphinus Medical Technologies Inc. is about to graduate. And, after 17 years of research and development and three rounds of venture capital totaling $58.5 million, it will start selling its first devices for ultrasonic detection […]

Read On ›
May 13, 2016

NeoChord Receives FDA Approval to begin Clinical Trial for Treatment of Degenerative Mitral Valve Regurgitation

ST. LOUIS PARK, Minn.–(BUSINESS WIRE)–NeoChord, Inc. today announced that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (FDA) to begin a prospective, multicenter, randomized clinical trial for […]

Read On ›
March 29, 2016

David H. Adams, MD and Michael A. Borger, MD, PhD to Serve as National Principal Investigators for NeoChord’s U.S. Pivotal Trial

ST. LOUIS PARK, Minn.–(BUSINESS WIRE)–NeoChord, Inc., a leader in advancing the treatment of minimally invasive repair of degenerative mitral valve regurgitation (DMR) without the use of cardiopulmonary bypass, today announced that David H. Adams, MD, […]

Read On ›
October 29, 2015

ProNAi Initiates ‘Brighton’ Phase II Trial of PNT2258 in Patients with Richter’s Transformation

VANCOUVER, Oct. 29, 2015 /CNW/ – ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced it has enrolled the first patient […]

Read On ›
October 15, 2015

Concerto opening additional clinics for Medicare-Medicaid patients in Detroit

Concerto Healthcare Inc., an Irvine, Calif.-based health care company, is opening its fourth metro Detroit clinic in western Detroit on Oct. 22 to serve the Medicare-Medicaid dual-eligible population in a pilot program overseen by the Michigan […]

Read On ›
September 10, 2015

Delphinus Raises Over $39 Million in Capital

PLYMOUTH TOWNSHIP, Mich. – Sept.10, 2015 – Delphinus Medical Technologies, Inc., the leader in advanced breast ultrasound technology, announced today that it has secured an unprecedented venture round of $39.5 million. The venture capital funding […]

Read On ›
July 21, 2015

ProNAi Therapeutics Announces Closing of IPO and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

VANCOUVER, July 21, 2015 /CNW/ – ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced the closing of its initial public […]

Read On ›
July 15, 2015

ProNAi Therapeutics Announces Pricing of Initial Public Offering

VANCOUVER, July 15, 2015 /CNW/ – ProNAi Therapeutics, Inc., a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced the pricing of its initial public offering […]

Read On ›
June 9, 2015

NEOCHORD SECURES $20 MILLION SERIES C FINANCING

EDEN PRAIRIE, MN, June 9, 2015—NeoChord Inc. – a medical technology company, announced today it has closed an oversubscribed $20 million Series C financing round led by Deerfield Management, with participation from Baird Capital’s Venture […]

Read On ›
March 18, 2015

Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease

 KALAMAZOO, Mich., March 18, 2015 – Metabolic Solutions Development Company (MSDC), an emerging biopharmaceutical company developing first in class therapeutics to treat diseases associated with metabolic dysfunction, today announced that Stephen Benoit, CEO, will present […]

Read On ›
January 12, 2015

ProNAi to Present at the 33rd Annual J.P. Morgan Healthcare Conference

 Vancouver, BC and Plymouth, MI – January 12, 2015. ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi® platform, today announced that […]

Read On ›
October 23, 2014

Metabolic Solutions Development Company Appoints Robert L. Zerbe, MD to Board of Managers

KALAMAZOO, Mich., October 23, 2014 – Metabolic Solutions Development Company, LLC (MSDC) announced today that it has appointed Robert L. Zerbe, MD to its Board of Managers. Dr. Zerbe co-founded and is chief executive officer […]

Read On ›
October 22, 2014

ProNAi Therapeutics Strengthens Senior Management Team to Advance DNAi®-based Oncology Therapeutics

 Vancouver, BC, Canada and Plymouth, MI, USA – October 22, 2014. ProNAi Therapeutics Inc., a private company dedicated to developing and commercializing a new class of therapies based on its proprietary DNAi® platform, today announced […]

Read On ›
September 3, 2014

ProNAi Therapeutics, Inc. Names New President and Chief Executive Officer

Plymouth, Ml-September 3, 2014. ProNAi Therapeutics, Inc., a developer of novel nucleic acid therapeutics, announces the appointment Nick Glover, Ph.D. as President and Chief Executive Officer. The company’s previous CEO, Mina Sooch, will be leaving […]

Read On ›
August 13, 2014

Alec Cunningham Joins Fidelis SeniorCare as President, CEO

August 13, 2014 12:00 PM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Fidelis SeniorCare (“Fidelis” or the “Company”), a successful pioneer and leader in the delivery of extraordinary clinical health care services for seniors, today announced the appointment […]

Read On ›
June 24, 2014

NeoChord Appoints David Chung as President and CEO

EDEN PRAIRIE, Minn., June 24, 2014—NeoChord, a medical device company focused on minimally invasive mitral valve repair, announced today that it has appointed David H. Chung as President and CEO, effective immediately, replacing John Seaberg, […]

Read On ›
April 21, 2014

ProNAi Therapeutics Raises $59.5 Million Series D Financing

Plymouth, MI—April 21, 2014. ProNAi Therapeutics, Inc., a developer of novel nucleic acid therapeutics, announced the closing of an oversubscribed $59.5 million Series D financing. The round was led by Vivo Capital of Palo Alto, […]

Read On ›
April 7, 2014

IT Startup Bjond Secures $3.25M to ‘Supercharge’ Legacy Care Management Systems

April 7, 2014 12:14 pm by Deanna Pogorelc Bjond Inc. is in the business of developing care management software for providers and payors. But the company isn’t necessarily looking to replace legacy care management systems […]

Read On ›
April 4, 2014

NeoChord Crosses 100th Patient Milestone; Appoints Michael Dale to Board of Directors

EDEN PRAIRIE, MN, April 4, 2014—NeoChord Inc., a developer of minimally invasive devices and procedures for mitral valve repair, today announced the treatment of its 100th patient.  “This is an important achievement for our Company, […]

Read On ›
January 6, 2014

Deerfield Announces up to $50 Million Investment in Fidelis SeniorCare

NEW YORK–(BUSINESS WIRE)– Monday, 6 Jan 2014 | 8:30 AM ET | Deerfield Management Company announced today that it has entered into a secured loan facility with Fidelis SeniorCare, Inc. for up to $50.0 million […]

Read On ›
December 18, 2013

Centene Corporation to Acquire Majority Stake in Fidelis SecureCare of Michigan

ST. LOUIS, Dec. 18, 2013 /PRNewswire/ — Centene Corporation (NYSE: CNC) (“Centene”) announced today that it has signed a definitive agreement to purchase a majority stake in Fidelis SecureCare of Michigan, Inc. (“Fidelis SecureCare”), a […]

Read On ›
September 9, 2013

MSDC Presents Phase 2a Clinical Trial Results at the 14th International Conference on Alzheimer’s Drug Discovery

 KALAMAZOO, Mich., /Sept. 9, 2013 – Metabolic Solutions Development Company, LLC (MSDC) has announced that Jerry Colca, PhD, co-founder and chief scientific officer of MSDC, will present results of a Phase 2a study on September […]

Read On ›
May 20, 2013

Fidelis Seniorcare Closes $20.5 Million Equity Financing

Schaumburg, Illinois – May 20, 2013 – Fidelis SeniorCare, Inc., a managed care company that administers Medicare Advantage Special Needs Plans to dual eligible and individuals living in long-term care facilities, announced the completion of […]

Read On ›
February 7, 2013

Metabolic Solutions Development Company Awarded Funding by The Michael J. Fox Foundation

KALAMAZOO, Mich., Feb. 7, 2013 – Metabolic Solutions Development Company, LLC (MSDC) announced today that it has received an award from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to conduct preclinical research on […]

Read On ›
January 24, 2013

Metabolic Solutions Development Company Announces Publication of Phase 2b Data in Clinical Pharmacology & Therapeutics

KALAMAZOO, Mich., Jan. 24, 2013 – Metabolic Solutions Development Company, LLC (MSDC) announced today the publication of data from a Phase 2b study of the company’s prototype insulin sensitizer in patients diagnosed with type 2 […]

Read On ›
January 3, 2013

NeoChord receives CE marking for DS1000 mitral valve repair device and plans first enrollments in TACT Registry for Q1 2013.

Initial registry training and proctoring to be provided by Leipzig Heart Center, Mayo Clinic and University of Pittsburgh Medical Center. TACT Trial results, recently reported at TCT and EACTS, show good safety and efficacy for […]

Read On ›
December 25, 2012

TransCorp Spine Surgical System Attracts National Peer-Review Award – Grand Rapids Business Journal

December 25, 2012 The Brain + Spine Center in Holland Township has announced that the SpinePort surgical system co-invented by the clinic’s neurosurgeon, Dr. David W. Lowry, and physician assistant Scott M. Tuinstra has received […]

Read On ›
October 16, 2012

Tolera Therapeutics closes Series B-3 financing, raises $5.5 million to submit Phase 3 Special Protocol Assessment for its immune targeting biologic drug in kidney transplantation

KALAMAZOO, Mich., Oct. 16, 2012 — /PRNewswire/ – Tolera Therapeutics Inc., a privately held biotechnology company focusing on the development of immunotherapeutics directed at the transplantation, autoimmune and oncology markets, announced today that it has closed […]

Read On ›
October 2, 2012

NeoChord Inc. Obtains Exclusive Rights to State-of-the-Art, Award-Winning ‘Augmented Reality’ Imaging Technology from Western University’s Robarts Research Institute

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Robust navigation platform integrates real-time transesophageal echo (TEE) with a magnetic tracking system that guides a surgeon to virtual images of target anatomy. “The ‘NeoNav’ imaging platform offers faster and easier navigation […]

Read On ›
October 1, 2012

Tolera Therapeutics Announces Appointment of Linda C. Hogan as Vice President, Business Development

KALAMAZOO, Mich., Oct. 1, 2012 – /PRNewswire/ – Tolera Therapeutics, Inc., a privately held biotechnology company focused on the development of immunotherapeutics directed at the transplantation, autoimmune and oncology markets announced today the appointment of Linda C. […]

Read On ›
September 18, 2012

Hopen Life Science Ventures Expands Leadership Team with Addition of Michael Fulton, M.D. as Managing Director; Opens Cleveland, Ohio Office to Strengthen Midwest Reach

Cleveland, OH (September 18, 2012) – Hopen Life Science Ventures, a Midwest-based venture capital firm, is pleased to announce the addition of Michael Fulton, M.D. as a managing director. Dr. Fulton has over 20 years […]

Read On ›
September 10, 2012

NeoChord Completes Enrollment for ‘TACT’ Clinical Trial

September 10, 2012 10:00 AM Eastern Daylight Time EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–   Acute and chronic results using NeoChord’s sternal-sparing, beating-heart, mitral valve repair system to implant artificial chordae tendinae are encouraging. NeoChord: “The 30-patient TACT […]

Read On ›
September 7, 2012

MSDC Presents Update on Ongoing Clinical Evaluation of First in Class mTOT Modulator™ in Mild Alzheimer’s Disease at 13th International Conference on Alzheimer’s Drug Discovery

KALAMAZOO, Mich., Sept. 7, 2012 /PRNewswire/ — Metabolic Solutions Development Company, LLC (MSDC) will provide an update on the clinical evaluation of MSDC-0160, a first in class mTOT Modulator™ that is being investigated in an […]

Read On ›
June 21, 2012

Researchers Study Potential New Therapeutic Target for Alzheimer’s Disease

KALAMAZOO, Mich., June 21, 2012 – Physicians at medical centers in Kalamazoo and Grand Rapids are helping to identify interested individuals for participation in a clinical trial of a novel drug therapy for patients with […]

Read On ›
June 11, 2012

TransCorp Spine Receives FDA 510(k) Clearance for the SpinePort™

Ada, Michigan – TransCorp Spine announced today that it received FDA 510(k) clearance for its SpinePort Spinal Access System.  The SpinePort System provides direct access and visualization to aide surgeons in treating cervical spine pathologies […]

Read On ›
June 9, 2012

Metabolic Solutions Development Company Novel Insulin Sensitizer Meets Phase 2b Study Endpoints And Affirms New Mechanism Of Action

PHILADELPHIA, June 9, 2012 – Metabolic Solutions Development Company, LLC (MSDC) presented Phase 2b results for MSDC-0160 today at the 72nd Scientific Sessions of the American Diabetes Association. The data showed this novel once-a-day oral […]

Read On ›
November 10, 2011

Hopen’s Mike Jandernoa to Receive “Spirit of Michigan” Award at Accelerate Michigan Innovation Competition’s Gala Awards

Dearborn, Mich. (November 10, 2011) The Accelerate Michigan Innovation Competition (AMIC) has announced that its 2011 “Spirit of Michigan” recipient is Mike Jandernoa. Each year a Michigan business person is chosen to receive the award […]

Read On ›
October 6, 2011

Metabolic Solutions Development Company Receives $1.1 Million NIH Grant to Further Investigate MSDC-0602 for the Treatment of Fatty Liver Disease

Kalamazoo, Mich. (October 6, 2011) – Metabolic Solutions Development Company, LLC (MSDC) announced today it has received a $1.1 million multi-year Small Business Technology Transfer Program (STTR) grant from the National Institute on Alcohol Abuse […]

Read On ›
September 8, 2011

Metabolic Solutions Development Company Reports Positive Top-Line Results from Phase 2A Study of its Second Compound to Treat Type 2 Diabetes

Kalamazoo, Mich. (September 08, 2011) – Metabolic Solutions Development Company, LLC (MSDC) confirmed today the potential of MSDC-0602 to achieve significant glucose control in type 2 diabetes patients and increase insulin sensitivity based on preliminary […]

Read On ›

Nymirum’s Hashim M. Al-Hashimi Recognized as “Molecular Filmmaker” in PopSci’s 10th Annual Brilliant 10

Early every morning, before dawn if he can, Hashim Al-Hashimi goes running. Six miles, rain or shine, summer heat or bitter Michigan cold (Al-Hashimi works at the University of Michigan). His chosen route is hilly… […]

Read On ›
August 4, 2011

Hopen Life Science Ventures Fund II Reaches $25 Million Initial Close and Announces First Four Investments

Grand Rapids, Mich. (August 4, 2011) – Hopen Life Science Ventures, a Grand Rapids-based life science venture capital fund, announced an initial close of $25 million for its second fund, Hopen Life Science Fund II. […]

Read On ›

Two heart-repair device firms pull in $7M

Minnetonka, Minn. (August 4, 2011) – Minnesota companies continue to pull in venture capital, with two multimillion-dollar money raises disclosed in recent U.S. Securities and Exchange Commission filings. Minnetonka-based NeoChord recently raised $5 million and […]

Read On ›
July 24, 2011

A tale of proteins and cells: Metabolic Solutions is trying to write next chapter with new diabetes, heart treatments – Kalamazoo Gazette

Kalamazoo, Mich. (July 24, 2011) – Metabolic Solutions Development Company was recently featured in the Kalamazoo Gazette putting the spotlight on the company’s efforts to develop novel treatments for metabolic diseases. Read the complete Kalamazoo […]

Read On ›
July 18, 2011

Investors put $7.2 million into life sciences firm Intervention Insights in Grand Rapids

Grand Rapids, Mich. (July 18, 2011) – The $7.2 million from a group of investors will help Intervention Insightsfurther commercialize a technology that enables oncologists to match cancer patients with drugs that work best on […]

Read On ›
July 6, 2011

MSDC Receives $773,000 from the Alzheimer’s Drug Discovery Foundation to Fund Phase 2a Trial

Kalamazoo, Mich. (July 06, 2011) – Metabolic Solutions Development Company (MSDC), a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has received a $773,000 grant from […]

Read On ›
June 21, 2011

MSDC to Present Recent Findings on the Therapeutic Potential of Increasing Brown Fat in the Treatment of Diabetes at Annual American Diabetes Association Conference

Kalamazoo, Mich. (June 21, 2011) – Metabolic Solutions Development Company (MSDC) and collaborators will present their research providing insights into the therapeutic potential of increasing brown adipose tissue in the treatment of diabetes and the […]

Read On ›
March 29, 2011

MSDC Launches Phase 2A Trial of Its Second Compound to Treat Type 2 Diabetes

Kalamazoo, Mich. (March 29, 2011) – Metabolic Solutions Development Company (MSDC), a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has launched a Phase 2a trial […]

Read On ›